RecruitingNCT05884983

Screening Effect of Dual-energy CT Combined With Nasopharyngeal Endoscopy for Screening Nasopharyngeal Carcinoma

Sponsor

Zhongshan People's Hospital, Guangdong, China

Enrollment

12,000 participants

Start Date

Feb 1, 2023

Study Type

OBSERVATIONAL

Conditions

Nasopharyngeal Carcinoma

Summary

All participants will be tested for EBV-related biomarkers, including EBNA1-IgA, VCA-IgA, and BNLF2b total antibody (P85-Ab), and participants with high serologic risk will be selected based on serologic test results, and dual-energy CT will be performed first for high-risk screening subjects, and dual-energy CT will be performed first for the high-risk group to record dual-energy CT examinations of those suspected of nasopharyngeal carcinoma, and then endoscopy was performed on the high-risk group to record those suspected of nasopharyngeal carcinoma under endoscopy, and finally biopsies were taken for positive lesion sites indicated by dual-energy CT and suspicious lesion sites found by endoscopy to clarify the diagnosis.

Eligibility

Min Age: 30 YearsMax Age: 69 Years

Plain Language Summary

Simplified for easier understanding

This study is testing whether combining a CT scan (using two types of X-ray energy) with a nasal endoscopy (a small camera examination of the nose and throat) can effectively screen for nasopharyngeal carcinoma — a cancer at the back of the nasal cavity — in people living in a high-risk region of China. **You may be eligible if...** - You live in Zhongshan City - You have no previous history of nasopharyngeal carcinoma - You are able to understand and sign the consent form - You are able to cooperate with follow-up visits **You may NOT be eligible if...** - You have serious heart, liver, or kidney disease - You have a reason you cannot safely undergo a nasal endoscopy - You are allergic to contrast dye used in CT scans Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

PROCEDUREparticipants will undergo dual-energy CT and endoscopy

Diagnostic Test: P85-Ab,EBNA1-IgA,and VCA-IgA. Detect P85-Ab, EBNA1-IgA, VCA-IgA for all participants and select serological high-risk participants DiagnosticTest: dual-energy CT, endoscopy and biopsy. serological high-risk participants will refer to dual-energy CT, endoscopy and biospy

Locations(1)

Zhongshan People's Hospital

Zhongshan, Guangdong, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05884983

Related Trials

[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers

NCT064798111 location

Maintenance Therapy With Toripalimab and Capecitabine Versus Capecitabine Alone in High-risk Nasopharyngeal Carcinoma

NCT062770503 locations

Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic Solid Tumors

NCT075844991 location

CD70-targeted immunoPET Imaging of Malignant Cancers

NCT068526381 location

Chemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III Trial

NCT0534049112 locations